Beta Drugs Limited has informed the Exchange about the acquisition of 66.09% stake in Nivian Lifesciences Private Limited.
BETA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Beta Drugs Limited has signed a definitive agreement to buy a 66.09% stake in Nivian Lifesciences Private Limited for INR 69.4 Crores, valuing Nivian at INR 105 Crores. Nivian operates in the branded IVF (In-Vitro Fertilisation) therapy segment in India, which is growing at about 20% CAGR and has a total market size of INR 1,500–1,700 Crores. Nivian, founded in 2019, reported net sales of INR 30.30 Crores for the 9 months ended Dec 2026 and is expected to close FY27 at around INR 43 Crores in revenue. The founder Nilesh Auti (ex-Bharat Serums) will continue to lead Nivian's marketing and operations. The deal gives Beta a platform to become a market leader in the Indian women's health and fertility drug market, combining Beta's manufacturing strengths with Nivian's IVF marketing capabilities.
This is a strategic entry into the fast-growing IVF and women's health segment, which should diversify Beta's revenue base and provide a new high-growth vertical alongside its existing oncology and cosmetology businesses. Positive for the stock as it signals expansion into a high-CAGR, niche therapy area, though investors should watch for execution and integration risks.